Researchers conducted a Phase 3 trial involving 407 patients aged 14 to 70. These patients had acute myeloid leukemia or myelodysplastic syndromes and were undergoing haploidentical peripheral blood stem cell transplants. The study compared three different ways to prevent graft-versus-host disease, which is a common complication where the body attacks its own tissues.
The trial found that all three treatment groups performed similarly in preventing severe acute reactions and maintaining survival rates at one year. However, patients who received a specific combination of low-dose antithymocyte globulin and posttransplant cyclophosphamide showed significantly faster recovery of neutrophils and platelets compared to the other two groups.
While some numbers suggested lower rates of chronic issues in certain groups, these results were not statistically significant. Because this study shows that different methods provide similar protection against immediate complications but vary in how quickly they restore blood counts, patients should talk to their doctors about which approach best fits their specific recovery needs.
